Últimas noticias sobre Nurix Therapeutics (NASDAQ:NRIX) Bolsa

NURIX THERAPEUTICS INC

Nurix Therapeutics

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Nurix Therapeutics Inc

UBS analyst Jay Sole maintains Palmer Square Capital BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSBD#NYSE">PSBD</a>) with a Neutral and raises the price target from $14 to $14.5.

News

Price Target

Analyst Ratings

PSBD

UBS Maintains Neutral on Palmer Square Capital BDC, Raises Price Target to $14.5

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) will release earnings results for the second quarter, before the <a href="https://www.benzinga.com/quote/abt/earnings">opening bell on Thursday, July 17.</a>
Analysts expect the North Chicago, Illinois-based company to report quarterly earnings at $1.25 per share, up from $1.14 per share in the year-ago period. Abbott Laboratories projects to report quarterly revenue at $11.02 billion, compared to $10.38 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 27, Abbott announced the U.S. Food and Drug Administration approved the company&#8217;s Tendyne&#x2122; transcatheter mitral valve replacement (TMVR) system to treat people with mitral valve disease.
Abbott Laboratories shares rose 0.1% to close at $131.49 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/abt/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Morgan Stanley analyst David Lewis maintained an Equal-Weight rating and raised the price target from $127 to $137 on July 15, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Raymond James analyst Jayson Bedford maintained an Outperform rating and boosted the price target from $132 to $142 on April 17, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Barclays analyst Matt Miksic maintained an Overweight rating and increased the price target from $158 to $159 on April 17, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Stifel analyst Rick Wise maintained a Buy rating and boosted the price target from $135 to $145 on April 17, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Jefferies analyst Matthew Taylor maintained a Hold rating and increased the price target from $135 to $137 on April 17, 2025. This analyst has an accuracy rate of 69%.</li>
</ul>
Considering buying ABT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/ABT/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16023805/image-186-1024x562.png" alt="" class="wp-image-987165" style="width:661px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16023805/image-186-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16023805/image-186-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16023805/image-186-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16023805/image-186.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46415122/top-2-tech-telecom-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Tech &amp; Telecom Stocks That May Keep You Up At Night This Month</a></li>
</ul>
Photo via Shutterstock

Earnings

Markets

Trading Ideas

Abbott Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

UBS analyst Lloyd Walmsley maintains Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) with a Buy and raises the price target from $44 to $50.

PINS

UBS Maintains Buy on Pinterest, Raises Price Target to $50

WIIM

SLNH

Soluna Holdings shares are trading lower after the company announced a $5 million common stock offering.

While the market absorbs a mixed bag of <a href="https://www.benzinga.com/markets/equities/25/07/46435439/dow-tumbles-over-400-points-as-inflation-rises-faster-than-expected-fear-index-moves-to-greed-zone">inflation reports</a> and Fed projections, focus is shifting back to earnings, <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46420414/bank-earnings-performance-q2-citigroup-jpmorgan-blackrock-wells-fargo">beginning with the largest banks</a>. Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) and Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) reported on Wednesday and their figures have the financial sector cheering.
But rather than stock-picking their way through spreadsheets and surprise provisions, <a href="https://www.benzinga.com/etfs">ETF investors</a> can take a more direct approach: positioning through financial sector funds that provide broad exposure to Wall Street&#8217;s largest names.
The earnings season started on a positive note on Tuesday. Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WC#NYSE">WC</a>) topped forecasts with higher-than-expected second-quarter adjusted EPS on July 15, benefiting from higher net interest income and careful cost discipline. Meanwhile, JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) also exceeded expectations, with solid performances from both its consumer and commercial banking segments.
These initial beats gave hope that the remainder of the large bank group— Goldman Sachs, Morgan Stanley, and Bank of America— could do the same, and they did today. 
Bank of America beat earnings estimates and saw revenue growth. Goldman Sachs also came ahead of estimates, as trading operations generated $840 million more revenue than expected. Morgan Stanley, too, beat earnings estimates on increased trading revenues.
This creates a key window now for ETF investors wanting to ride or hedge against banking sector volatility.
<h2 class="wp-block-heading">The ETF Earnings Playbook: Financials In Focus</h2>
Bank stocks can sometimes serve as macroeconomic health indicators. Loan expansion, consumer credit, investment banking work, and trading revenues all speak to a larger economic tale. And when sentiment is soaring (as it is currently, with the CNN Fear &amp; Greed Index in the &#8220;Greed&#8221; range), financials may receive a boost or a beating from even small surprises.
Three ETFs are in the limelight this earnings season:
Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>): The fund, which has an expense ratio of 0.08%, has leadership holdings in JPMorgan Chase, Bank of America, Wells Fargo, Goldman Sachs, and Morgan Stanley.
Why it matters: XLF is the favorite ETF among retail and institutional investors for financials. It&#8217;s diversified across large-cap banks, insurers and asset managers.
The trade: Bullish on big banks beating earnings estimates? XLF provides broad but concentrated exposure.
SPDR S&amp;P Bank ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBE#NYSE">KBE</a>): This fund has an expense ratio of 0.35% and has exposure to large and regional banks. Among the top holdings are Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NASDAQ">TBBK</a>), Citigroup Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), and Northern Trust Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRS#NASDAQ">NTRS</a>).
Why it matters: KBE equal-weights its positions, so it&#8217;s not controlled by the megabanks. That makes it a good bet if you believe the regional banking sector will surprise to the upside, or just remain stable after a rough year.
The trade: Use KBE to get a better handle on the banking sector, particularly if you anticipate positive news beyond the household names.
SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>): Top holdings: Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), and, yes, the banks.
Why it matters: SPY is not a financials ETF, but banking earnings tend to lead the overall market in terms of setting the tone. Positive bank earnings can boost investor sentiment across the board.
The trade: For those who think banks will lead the momentum and enhance risk appetite, SPY is a means to participate in that without committing to a single sector.
Although the hot <a href="https://www.benzinga.com/markets/economic-data/25/07/46413961/june-inflation-cpi-report">headline inflation print </a>was at 2.7% YoY, core inflation surprisingly came in lower. That could be a green light for the banks, particularly if interest rate expectations are maintained and the loan books are healthy.
Despite this, not everything is rosy. The Dow fell by over 400 points on Tuesday and healthcare and materials pulled the S&amp;P 500 down. But Nasdaq jumped to new highs following Nvidia&#8217;s AI-powered chip romp, illustrating just how divided the market is.
<h2 class="wp-block-heading">Know Your Risk, Pick Your Basket</h2>
Earnings season is never predictable, but with ETFs, you don&#8217;t have to choose winners and losers stock by stock. Let the sector and investor sentiment do the heavy lifting.
So, whether you&#8217;re placing your bets on big beats or hedging against a letdown, ETFs such as XLF, KBE and SPY provide diversified, accessible ways to make your perspective a reality.
Because nothing speaks greed like doubling down on bank earnings, through ETFs.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/07/46423852/nvidias-china-chip-deal-signals-new-tailwind-for-chip-and-ai-etfs">Nvidia&#8217;s China Chip Deal Signals New Tailwind For Chip And AI ETFs</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

ETFs

AAPL

MSFT

NTRS

NVDA

TBBK

ETF Playbook For Bank Earnings: Big Bets On Goldman, Morgan Stanley, BofA

TDTH

Trident Digital Tech Holdings shares are trading higher after the company announced it signed a public-private partnership with the government of the Democratic Republic of Congo to launch the nationwide Web 3.0 digital ID system.

Klotho Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) announced on Wednesday that it has received notification from Nasdaq that KLTO stock has full compliance with all continued listing requirements and will remain listed and traded on the <a href="https://www.benzinga.com/pressreleases/25/07/n46437168/klotho-neurosciences-inc-regains-full-compliance-with-nasdaq-minimum-closing-bid-price-and-stockho">Nasdaq Stock Market</a>
What To Know: Klotho has regained compliance with both the minimum $1.00 bid price&nbsp; and the minimum stockholders&#8217; equity threshold requirements.&nbsp;&nbsp;
See Also: <a href="https://www.benzinga.com/markets/tech/25/07/46422009/rare-earth-royalty-meet-the-power-players-shaping-the-industry?utm_source=articleShare">Rare Earth Royalty: Meet The Power Players Shaping The Industry</a>
Nasdaq will continue to monitor Klotho's ongoing compliance with the stockholders&#8217; equity threshold requirement for one year.&nbsp;
The company could become subject to delisting without a cure period if it falls out of compliance in that time, but will have the opportunity to request a new hearing should that event occur.
What Else: Klotho recently announced<a href="https://www.benzinga.com/pressreleases/25/07/n46337387/klotho-neurosciences-inc-granted-fda-orphan-drug-designation-for-klto-202-for-treatment-of-amyotro"> it had received </a>FDA Orphan Drug Designation for its ALS therapy candidate, unlocking seven years of market exclusivity, tax credits and regulatory assistance as the <a href="https://www.benzinga.com/markets/biotech/25/07/46345543/klotho-stock-delivers-1222-biotech-blowout-opportunity-or-bubble">potential treatment </a>moves through the approval process.&nbsp;
Klotho stock has gained more than 200% over the past six months on a series of announcements including positive preclinical results and the elimination of debt from its balance sheet.&nbsp;
KLTO Stock Price: Shares of Klotho Neurosciences were up 5.62% at $82.00 in Wednesday's session, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro.</a>&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46374434/joby-aviation-stock-goes-vertical-as-secret-massive-drone-achieves-9-hour-flight?utm_source=articleShare">Joby Aviation Stock Goes Vertical As Secret, Massive Drone Achieves 9-Hour Flight</a></li>
</ul>
Image: Shutterstock

Biotech

Penny Stocks

Small Cap

Movers

General

KLTO

Klotho Clears Nasdaq Hurdle—KLTO Stock Remains On The Big Board

Jim Cramer&nbsp;has a message for&nbsp;Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>): Stop recycling your cash and start reimagining the future. <a href="https://www.benzinga.com/topic/jim-cramer">The &#8220;Mad Money&#8221; host</a> isn't mincing words—he wants Apple to stop pouring billions into stock buybacks and instead invest the cash hoard in a brain.
Translation? Ditch the financial engineering and acquire cutting-edge AI talent, tech, and tools—like red-hot Perplexity—to supercharge innovation.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Yes if Apple buys Perplexity we would have our winning bot and the stock would soar. Continued buybacks will do nothing Sigh
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1945416220708077638?ref_src=twsrc%5Etfw">July 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Also: <a href="https://www.benzinga.com/node/46435562">Apple Strikes $500 Million Deal With MP Materials To Reduce China Reliance On Critical Magnets</a>
<h2 class="wp-block-heading">Buybacks: Apple's Favorite Snoozefest</h2>
With a $3 trillion market cap and a $110 billion buyback plan, Apple's cash strategy is as exciting as watching your iPhone update overnight. Sure, buybacks boost EPS and support the stock, but they don't exactly scream future-forward. 
Cramer says it's time for Cupertino to break its cycle of cash hoarding and repurchasing and start thinking like a tech company again.
<h2 class="wp-block-heading">Buy A Brain: Cramer's Call For An AI Wake-Up</h2>
It&#8217;s Cramer-speak shorthand: Apple doesn't just need AI features — it needs to buy a brain and embed it deep in its DNA. That could mean scooping up Perplexity, the AI darling behind the Comet browser, whose capabilities could finally give Siri a much-needed IQ boost. Imagine a Siri that doesn't just understand, but anticipates, outperforms Alexa, and becomes the crown jewel of every iPhone.
<h2 class="wp-block-heading">Perplexity: The AI Power Move Apple Won't Make (But Should)</h2>
Perplexity's tech is catching fire, and Cramer thinks it's exactly what Apple needs to leapfrog&nbsp;Meta Platforms Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and&nbsp;Alphabet Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google in the AI race.
The catch? Apple's M&amp;A history is notoriously timid. Their biggest moves are usually software updates, not splashy deals. But if there were ever a time to shake things up, it's now.
<h2 class="wp-block-heading">Genius Play Or Meme-Worthy Miss?</h2>
Cramer's take has the internet buzzing. Bulls say a bold AI acquisition could reignite Apple's innovation engine and stock. Skeptics say it's just another Cramer-ism destined for X sarcasm. 
Either way, his point stands: Apple can't afford to sit out the AI revolution armed with buybacks and nostalgia.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/node/46427933">Apple Stock A Back-To-School Winner? Nine States Offer Sales Tax Holidays, Big Savings</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Buybacks

Tech

GOOG

GOOGL

Cramer To Apple: Kick The Buyback Addiction - Buy A Brain Instead

UBS analyst Vilas Abraham maintains PennantPark Floating Rate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) with a Neutral and raises the price target from $10.5 to $10.75.

PFLT

UBS Maintains Neutral on PennantPark Floating Rate, Raises Price Target to $10.75

RBLX

Roblox shares are trading higher after JP Morgan maintained an Overweight rating and raised its price target from $120 to $125.

UNFI

United Natural Foods shares are trading higher after the company raised its FY25 sales guidance.

UBS analyst Michael Goldsmith maintains Netstreit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTST#NYSE">NTST</a>) with a Buy and raises the price target from $18 to $20.

NTST

UBS Maintains Buy on Netstreit, Raises Price Target to $20

Jensen Huang, CEO of Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), expressed admiration for Chinese EV maker Xiaomi Corp.&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>) newest electric cars during a high-profile<a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46436493/nvidias-china-revenue-is-far-from-gone-but-it-outmaneuvered-us-for-rare-earth-in-exchange-for-ai-chips-says-craig-shapiro" rel="noreferrer noopener"> visit to China this week.</a>
While attending the third China International Supply Chain Expo, Huang remarked that he would be thrilled to own a Xiaomi EV, praising both the company&#8217;s rapid rise and the broader evolution of China&#8217;s electric vehicle market, <a target="_blank" href="https://cnevpost.com/2025/07/16/nvidia-jensen-huang-love-to-buy-xiaomi-car/" rel="noreferrer noopener">reports </a>CnEV Post.
Huang highlighted Xiaomi&#8217;s impressive momentum despite being a late entrant into the EV space.
Also Read:<a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46440132/bezos-huang-cook-hit-sell-what-do-they-know-that-wall-street-doesnt" rel="noreferrer noopener"> Bezos, Huang, Cook Hit Sell—What Do They Know That Wall Street Doesn&#8217;t?</a>
He credited China&#8217;s auto and tech ecosystem for creating what he described as one of the most astonishing industrial transformations of the past five years.
Huang also noted that AI technology now powers a broad range of China&#8217;s digital infrastructure, including platforms like WeChat, Taobao, Douyin—and Xiaomi&#8217;s smart driving features.
Xiaomi recently rolled out its SU7 sedan line, which has maintained delivery volumes above 20,000 units monthly for nine straight months.
Its newly unveiled YU7 SUV garnered 200,000 orders within just three minutes of launch.
The SU7 runs on Nvidia&#8217;s Orin chip, while the YU7 is equipped with the newer Thor chip.
Though Nvidia remains a top choice for China&#8217;s EV chip needs, companies like Nio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) and Xpeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) have begun integrating self-designed chips in newer vehicles.
Xiaomi itself has developed an in-house chip, Xring O1, currently used in its mobile devices but not yet deployed in its cars.
Beyond his praise for China&#8217;s EV landscape, Huang also recently weighed in on broader geopolitical and regulatory dynamics impacting Nvidia.
In a separate <a target="_blank" href="https://www.cnbc.com/2025/07/14/nvidias-jensen-huang-downplays-us-china-concerns-ahead-of-trip.html" rel="noreferrer noopener">interview </a>with CNN, Huang clarified that Nvidia&#8217;s chips are not utilized by China&#8217;s military, attributing this to strict export regulations.
He explained that China has developed ample domestic computing infrastructure and would not rely on American chipsets for defense needs.
Speaking to reporters at the Mandarin Oriental hotel in Beijing, Huang also welcomed Nvidia&#8217;s return to the Chinese market with its H20 AI chip.
He hinted this development may be linked to broader geopolitical trade discussions involving rare earth exports.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/node/46395825" target="_blank" rel="noreferrer noopener">Nvidia Vs. Microsoft Vs. Apple: Who Will Hit $5 Trillion Market Cap First? 75% Of Readers Pick This Stock</a></li>
</ul>
Photo: jamesonwu1972/Shutterstock.com

Equities

XIACF

XPEV

Why Nvidia's Huang Would Be Thrilled To Own A Xiaomi EV

BTBT

Bit Digital shares are trading higher after its subsidiary, WhiteFiber, announced it will file for an IPO.

UBS analyst Vilas Abraham maintains Nuveen Churchill Direct (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCDL#NYSE">NCDL</a>) with a Neutral and raises the price target from $16.5 to $17.5.

NCDL

UBS Maintains Neutral on Nuveen Churchill Direct, Raises Price Target to $17.5

ARDT

Ardent Health shares are trading lower after B of A Securities downgraded the stock from Neutral to Underperform and cut its price target from $15.5 to $14.6.

RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) with a Outperform and lowers the price target from $68 to $53.

CGON

RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $53

Macro Economic Events

Market Summary

Economics

ASML

Benzinga Market Summary: ASML Falls On Uncertain Guidance, Morgan Stanley Falls On Earnings Report, PPI Comes In Below Estimates

UBS maintains MSC Income Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSIF#NYSE">MSIF</a>) with a Neutral and raises the price target from $15.5 to $16.5.

MSIF

UBS Maintains Neutral on MSC Income Fund, Raises Price Target to $16.5

Joby Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>), a pioneer in electric vertical takeoff and landing (eVTOL) aircraft, has seen its stock price surge, reflecting growing investor confidence in its commercialization prospects.
The stock has climbed 92% year-to-date and a remarkable 169% in the last three months, significantly outperforming the NYSE Composite Index, which gained 7% and 11% respectively over the same periods.
Joby initially entered the public market in 2021 through a Special Purpose Acquisition Company (SPAC) merger. The company currently generates most of its revenue from flight services under U.S. government contracts and early commercial operations, particularly with the Air Force.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46363784/boeing-joby-aviation-oracle-and-a-health-care-stock-cnbcs-final-trades" rel="noreferrer noopener">Boeing, Joby Aviation, Oracle And A Health Care Stock: CNBC&#8217;s &#8216;Final Trades&#8217;</a>
However, Joby&#8217;s long-term strategy centers on a significant revenue expansion through the launch of commercial air taxi services using its eVTOL aircraft.
This ambitious plan is now being underpinned by substantial progress in manufacturing and a supportive regulatory environment. The stock&#8217;s recent ascent of over 61% in the past 30 days highlights the positive market reaction to these developments.
<h2 class="wp-block-heading">Bolstering Production Capacity</h2>
Joby&#8217;s stock received a notable boost on Tuesday following the announcement of <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46419322/joby-stock-is-moving-higher-tuesday-whats-going-on" rel="noreferrer noopener">expanded manufacturing operations</a> at its facilities in California and Ohio, alongside the addition of new aircraft to its fleet.
The company has effectively doubled its production capacity at the Marina, California site, which now spans 435,500 square feet.
Concurrently, operations have been ramped up at its Dayton, Ohio facility, focusing on the production and testing of aircraft components.
This expansion is crucial for Joby&#8217;s push towards scaling commercial operations. The Marina site is projected to produce up to 24 aircraft per year, a significant step towards mass production.
Furthermore, this facility will serve as a hub for flight testing, pilot training, and critical Federal Aviation Administration (FAA) certification processes.
Eric Allison, Joby&#8217;s Chief Product Officer, emphasized the company&#8217;s readiness for rapid scaling, noting the swift airworthiness certification of their sixth aircraft just one week after its completion.
Joby also plans to leverage the renowned manufacturing expertise of Toyota Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>), a key investor, to eventually build up to 500 aircraft annually at the Dayton facility.
<h2 class="wp-block-heading">Regulatory Tailwinds Propel Growth</h2>
The positive momentum in Joby&#8217;s stock has been further amplified by a favorable shift in the regulatory landscape. On June 11, President Donald Trump&#8217;s <a target="_blank" href="https://www.benzinga.com/markets/equities/25/06/45896929/trump-launches-aviation-overhaul-archer-joby-new-horizon-aerovironment-rally-as-us-targets-drone-evtol-supersonic-comeback" rel="noreferrer noopener">new executive orders</a>, aimed at reasserting America&#8217;s aviation leadership, provided a significant boost.
These orders seek to streamline regulatory processes and include initiatives like the eVTOL Integration Pilot Program, designed to accelerate the commercial deployment of electric air taxis.
This move triggered a rally across aviation stocks, with Joby shares rising over 2% immediately after the announcement. The White House&#8217;s commitment to fostering domestic drone and eVTOL development directly aligns with Joby&#8217;s mission, potentially expediting its market entry and unlocking substantial long-term growth opportunities across defense, cargo, and urban mobility sectors.
Adding to this regulatory support, in June, FAA Acting Administrator Chris Rocheleau publicly <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/46125984/why-joby-and-archer-aviation-shares-are-soaring-thursday" rel="noreferrer noopener">reaffirmed the agency&#8217;s</a> dedication to the safe integration of electric air taxis into U.S. airspace.
This statement served as a vital regulatory endorsement for Joby, which is actively developing a five-seat electric aircraft for global passenger service, backed by strategic partners such as Toyota and Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>).
The FAA&#8217;s clear stance reinforces Joby&#8217;s path to commercialization as it spearheads the transformation of urban transportation.
<h2 class="wp-block-heading">Expert Insights</h2>
Recent expert opinions and company milestones further underscore Joby&#8217;s promising trajectory. A Hunterbrook Media report last week <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46374434/joby-aviation-stock-goes-vertical-as-secret-massive-drone-achieves-9-hour-flight" rel="noreferrer noopener">indicated significant progress</a>, claiming Joby has discreetly begun testing a long-range, hydrogen-powered Unmanned Aerial Vehicle (UAV) dubbed the JAI 30.
While Joby has not officially confirmed this project, flight tracking data, though briefly accessible online before being removed at the company&#8217;s request, suggested the JAI 30 has already completed a flight exceeding nine hours, positioning it among the longest-endurance hydrogen UAVs in its class.
Another notable endorsement came last week from Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, who selected Joby as his <a target="_blank" href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46363784/boeing-joby-aviation-oracle-and-a-health-care-stock-cnbcs-final-trades" rel="noreferrer noopener">&#8220;final trade&#8221;</a> on CNBC.
This pick followed Joby&#8217;s recent announcement on June 30 of successfully completing piloted vertical takeoff and landing flights of its electric air taxi in Dubai.
This achievement marks a crucial step toward launching commercial service in the region by 2026, a development that saw the stock <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/46172967/why-joby-aviation-stock-hit-a-new-52-week-high-today" rel="noreferrer noopener">reach</a> its 52-week high.
In July, <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight" rel="noreferrer noopener">when questioned about Joby</a>, CNBC&#8217;s Jim Cramer expressed confidence, stating, &#8220;Archer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) and Joby, what can I say? I&#8217;m not going to fight them.&#8221;
Price Action: JOBY stock is trading higher by 15.1% to $15.98 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46437647/xpeng-founder-reveals-bold-plan-to-hire-8000-more-by-2025" target="_blank" rel="noreferrer noopener">XPeng Founder Reveals Bold Plan To Hire 8,000 More By 2025</a></li>
</ul>

ACHR

JOBY

Joby Aviation Stock Soars 169% In 3 Months: What's Driving The Surge?

Health Care

Press Releases

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Comments

Nurix Therapeutics

Noticias

Últimas noticias sobre Nurix Therapeutics (NASDAQ:NRIX) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL